Stay updated with breaking news from Erick Lucera. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sioux Falls, SD , March 29, 2024 -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release during 2024 ...
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release during 2024 ...
Editas Medicine, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.52.
Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript February 28, 2024 Editas Medicine, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.52. EDIT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to Editas […]
Editas Medicine, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.52.